Iron removal machine for MDS or myelofibrosis with high iron
Part of Blood & lymphatic clinical trials.
This trial tests a new way to remove extra iron from the blood using a machine (like dialysis). It is for people with myelodysplastic syndrome or myelofibrosis who have severe anemia, high iron levels, and cannot take standard iron-removal pills or injections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with myelodysplastic syndrome or myelofibrosis.
- Your hemoglobin (red blood cell level) is very low—less than 7 g/dL.
- You cannot take oral or injected iron-removal medicines because you can't tolerate them or have a medical reason not to.
- You have high iron levels in your body (ferritin over 1000 µg/L, or liver iron at a certain level, or heart iron measurement too low).
- You are not taking certain other treatments for your blood disorder (like azacitidine, erythropoietin, or luspatercept) right now.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called DISC-0974 for people with myelofibrosis or certain types of MDS who have low red blood cell counts (anemia). The goal is to see if this treatment can help improve anemia and reduce the need for blood transfusions.
This trial tests three different treatments for people with a type of bone marrow disorder called low-risk myelodysplastic syndrome (MDS) that causes low red blood cells (anemia). The goal is to see which treatment works best and to find out more about the disease.
This Phase 2 study tests SP-420 to help people with transfusion-related iron overload from either beta-thalassemia or low-risk myelodysplastic syndromes. It aims to see if the treatment can improve how the body handles excess iron, which builds up after repeated transfusions.
This trial tests a new drug called elritercept against a standard treatment, epoetin alfa, for people with a low-risk form of MDS who need regular blood transfusions for anemia. The goal is to see if elritercept works better to reduce the need for transfusions.
This trial tests an experimental drug called PMD-026 for people with myelofibrosis that has not responded well to a JAK inhibitor (like ruxolitinib). The goal is to see if PMD-026 can help reduce symptoms and spleen size.
This trial tests a machine that picks out healthy stem cells for a bone marrow transplant. It may help people with certain blood cancers or disorders get a transplant with fewer complications.
Hear when a new Myelofibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.